Nerve Damage

EQS-News: First Surgery with Medacta's Minimally Invasive M.U.S.T. MC Platform

Retrieved on: 
Wednesday, September 29, 2021
Minimally invasive procedure, Nonunion, Trauma, Spondylolisthesis, Neoplasm, NASS, North American Spine Society, Patient, Solution, CT, Radiation exposure, Surgeon, Bleeding, Nerve Damage, MC, Education, Knowledge, Risk, Degenerative disc disease, Sacrum, Spinal stenosis, Ecosystem, Dentistry, Medical imaging

MC Platform

Key Points: 
  • MC Platform
    First Surgery with Medacta's Minimally Invasive M.U.S.T.
  • of Midlands Orthopaedics & Neurosurgery in Columbia, South Carolina successfully completed the first posterior lumbar fusion utilizing the company's minimally invasive M.U.S.T.
  • MC Platform features MySpine MC , a minimally invasive, patient-specific solution that may increase [1] screw placement accuracy, developed on the basis of the success of Medacta Patient-Matched Technology, which is part of the MySolutions(R) Personalized Ecosystem.
  • MC Platform seamlessly integrates the MySpine MC, placing personalized medicine at the forefront providing surgeons patient-specific anatomical information before they enter the operating room.

Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage

Retrieved on: 
Monday, September 27, 2021
ACST, Securities Act of 1933, Review, Death, Stroke, Micelle, Bleeding, Safety, Calendar, Blood pressure, Subarachnoid hemorrhage, Compliance, Drug Quality and Security Act, CRU, IV, Central nervous system, SubArachnoid Space, Private Securities Litigation Reform Act, Disability, BA, SAH, Capsule, Incidence, Brain, Orphan, Aneurysm, Water, NASDAQ, U.S. Securities and Exchange Commission, FDA, Nimodipine, Experimental cancer treatment, A-T, Marketing, Acquisition, Company, Vital signs, DCI, GLOBE, PHN, Grace, PK, Risk, TSX, Security (finance), Skull, Postherpetic neuralgia, Patient, Nerve Damage, Rupture, COVID-19, Securities Exchange Act of 1934, Neuropathic pain, Blood, ASAH, Cryptocurrency, Pharmaceutical industry, Medical imaging

This latest study follows an earlier safety and dose-escalation crossover study conducted by Grace, which reported encouraging results.

Key Points: 
  • This latest study follows an earlier safety and dose-escalation crossover study conducted by Grace, which reported encouraging results.
  • Moreover, it could provide a more convenient dosing schedule that would be easier to administer to patients who are unconscious.
  • The PK bridging study is a single center, randomized, two-period crossover study in 50 healthy subjects.
  • Acasti is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.

Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards

Retrieved on: 
Wednesday, September 22, 2021
ACST, PHN, Securities Act of 1933, Subarachnoid hemorrhage, Review, Compliance, Risk, TSX, Skull, Postherpetic neuralgia, NASDAQ, FDA, A-T, Nerve Damage, SubArachnoid Space, Marketing, Private Securities Litigation Reform Act, Disability, Company, SAH, COVID-19, Bleeding, Brain, Neuropathic pain, Securities Exchange Act of 1934, SEC, GLOBE, Pharmaceutical industry

Jan DAlvise, President and Chief Executive Officer of Acasti Pharma, commented, We are pleased to have regained compliance with the listing requirements for Nasdaq, and are laser focused on the integration of Grace Therapeutics, which is progressing seamlessly.

Key Points: 
  • Jan DAlvise, President and Chief Executive Officer of Acasti Pharma, commented, We are pleased to have regained compliance with the listing requirements for Nasdaq, and are laser focused on the integration of Grace Therapeutics, which is progressing seamlessly.
  • Specifically, these drug candidates are designed to achieve faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery.
  • Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases.
  • Acasti undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Emery Pharma Files an FDA Citizen Petition on Vitamin B6 Toxicity and Urges Warning Label

Retrieved on: 
Tuesday, September 21, 2021
NDMA, Food, Food and Drug Administration, OTC, Peripheral neuropathy, NMR, FDA, Patient, Microbiology, Pharmacy, Population, Hypoesthesia, LC-MS/MS, San Francisco Bay Area, Nerve Damage, Cell biology, HPLC, Toxicity, Nuclear magnetic resonance spectroscopy, CEO, CA, K-1 visa, Risk, Neurotoxicity, COVID-19, UPLC, Vitamin, Vitamin B6, Infection, NIH, Safety, DEA, Environment, United Kingdom, Dietary supplement

Emery Pharma also requests the agency to include a warning on the drug label regarding the danger of neurotoxicity for all Vitamin B6 products sold in the United States.

Key Points: 
  • Emery Pharma also requests the agency to include a warning on the drug label regarding the danger of neurotoxicity for all Vitamin B6 products sold in the United States.
  • More importantly, consumer education around the topic is crucial, hence, we request a warning label on all Vitamin B6 products.
  • Emery Pharma urges the Food and Drug Administration to implement safe guidelines for the use of this widely used and abused vitamin.
  • We request that the commissioner implement the below recommendations:
    1) Ask manufacturers of Vitamin B6 or B-Complexes to include labeling regarding the potential toxicity of Vitamin B6.

Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21ˢᵗ

Retrieved on: 
Tuesday, September 14, 2021
Neuropathic pain, Oppenheimer, Medtech, FDA, PHN, Marketing, Postherpetic neuralgia, Bleeding, A-T, ACST, Disability, RSVP, NASDAQ, Skull, Subarachnoid hemorrhage, Brain, SubArachnoid Space, GLOBE, Compliance, Finance, TSX, SAH, Nerve Damage, Pharmaceutical industry

LAVAL, Qubec, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today announced that it will be presenting at the Oppenheimer Fall Healthcare Summit being held virtually September 20-23, 2021.

Key Points: 
  • LAVAL, Qubec, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today announced that it will be presenting at the Oppenheimer Fall Healthcare Summit being held virtually September 20-23, 2021.
  • Jan DAlvise, President and Chief Executive Officer of Acasti Pharma, is scheduled to present on Tuesday, September 21, 2021 at 2:05 PM Eastern Time.
  • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit will feature presentations and one-on-one meetings in a virtual format with a select group of public companies in the Healthcare Life Sciences and MedTech arena.
  • Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases.

Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.

Retrieved on: 
Monday, September 13, 2021
Alzheimer's disease, Multiple sclerosis, Remyelination, Patient, Regeneration, Research, Neuroregeneration, NGEN, Sigma, Communication, Disclosure, Nerve Damage, Awareness, Pharmaceutical industry

Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF).

Key Points: 
  • Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF).
  • Encode Ideas, L.P., a healthcare focused research firm, announced today it is initiating coverage on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF).
  • Encode Ideas, L.P. is a healthcare focused research firm, founded in 2019, providing institutional quality research and investment ideas.
  • Encode Ideas, L.P. has been retained by NervGen, Inc. to provide investor awareness and research coverage.

Opium (Opioid) Addiction Drug Pipeline Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 9, 2021
Pharmaceutical, Health, Mental Health

Opium (Opioid) Addiction - Drugs In Development, 2021, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Key Points: 
  • Opium (Opioid) Addiction - Drugs In Development, 2021, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.
  • The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).- The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • - The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)

20 years later, the Hereditary Neuropathy Foundation brings back its "eye-catching" PSA in support of Charcot-Marie-Tooth Awareness Month

Retrieved on: 
Wednesday, September 1, 2021
Industry, Nerve Damage, Friends, Quality of life, Muscle atrophy, Peripheral neuropathy, Gene, Charcot–Marie–Tooth disease, Public service, Diagnosis, Family, Social media, CMT, Research, Government, Drug discovery, PSA, Disease, HNF, Awareness, Injury, Acupuncture & Electro-Therapeutics Research, Multimedia, Bullying, Public service announcement, The, Motion, Chronic pain, Patient, Self-care, Atrophy, CEO, Movement, Physical education, Facebook, Muscle weakness, View, Drug development, Pharmaceutical industry, Nightclub, Online shopping

NEW YORK, Sept. 1, 2021 /PRNewswire/ -- The Hereditary Neuropathy Foundation (HNF), an advocacy and research non-profit 501(c)3 organization, today brings back its "eye-catching" Public Service Announcement (PSA) 20 years after it was initially launched.

Key Points: 
  • NEW YORK, Sept. 1, 2021 /PRNewswire/ -- The Hereditary Neuropathy Foundation (HNF), an advocacy and research non-profit 501(c)3 organization, today brings back its "eye-catching" Public Service Announcement (PSA) 20 years after it was initially launched.
  • Currently, thousands of people with CMT are undiagnosed, yet are suffering with the symptoms of this chronic and often disabling disease.
  • Children are often pushed into Physical Education class and other activities that are not adapted to their special needs.
  • Show your support for CMT families and increase awareness across the globe by updating your Facebook profile photo with your exclusive frame.

Outlook on the Hemodialysis Global Market to 2026 - by Segment, Modality, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 31, 2021
General Health, Health, Other Health, Industry, Nerve Damage, Chronic kidney disease, Urea, Alcoholism, Blood pressure, Blood, Calcium, Growth, Kidney, Adoption, ESRD, Diagnosis, Salt, Diabetes, Sodium, Sexual abuse, Research, Prevalence, R, Health, Automation, Mineral, Awareness, Creatinine, CKD, Hypertension, Potassium, COVID-19, Pharmaceutical industry, Medical device, Potash

It removes waste products such as creatinine and urea from the blood and improves the functioning of the kidneys.

Key Points: 
  • It removes waste products such as creatinine and urea from the blood and improves the functioning of the kidneys.
  • Key Questions Answered in This Report:
    How has the global hemodialysis market performed so far and how will it perform in the coming years?
  • What are the key driving factors and challenges in the global hemodialysis industry?
  • What is the structure of the global hemodialysis industry and who are the key players?

Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split

Retrieved on: 
Friday, August 27, 2021
Company, Postherpetic neuralgia, Nerve Damage, Hoskin, LLC, Securities Exchange Act of 1934, PHN, KPMG LLP, Securities Act of 1933, Osler, Hoskin & Harcourt, Skull, GLOBE, Acquisition, SEC, William Blair & Company, Board of directors, Research, SubArachnoid Space, Disability, Neuropathic pain, Private Securities Litigation Reform Act, LLP, Marketing, Oppenheimer Holdings, AGSM, Intellectual property, ACST, Review, Risk, Board, Bleeding, NASDAQ, KPMG, Compliance, Subarachnoid hemorrhage, Circular, FDA, Remuneration, Brain, COVID-19, A-T, SAH, Pharmaceutical industry, Holding company, Security (finance)

The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases.

Key Points: 
  • The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases.
  • We believe the Grace acquisition will be truly transformative, creating new and exciting opportunities for us in sizable markets with substantial unmet medical needs.
  • In connection with the transaction, Grace was merged with a new wholly owned subsidiary of Acasti and became a subsidiary of Acasti.
  • At the AGSM, shareholders approved the issuance of Acasti shares as consideration to Grace securityholders pursuant to the merger.